Last reviewed · How we verify
iNeo-Vac-P01
At a glance
| Generic name | iNeo-Vac-P01 |
|---|---|
| Also known as | Neoantigen peptides |
| Sponsor | Zhejiang Provincial People's Hospital |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Neoantigen Vaccine in Esophagus Cancer Patients Following Neoadjuvant Therapy and Surgical Resection (PHASE1)
- Autologous Neoantigen-Specific T-Cell Therapy for Advanced Hepatocellular Carcinoma (PHASE1, PHASE2)
- Clinical Study of a Personalized Neoantigen Cancer Vaccine in Treating Patients With Advanced Pancreatic Cancer (PHASE1)
- Clinical Study of a Personalized Neoantigen Cancer Vaccine in Treating Patients With Advanced Malignant Tumor (PHASE1)
- Personalized Neoantigen Vaccine in Pancreatic Cancer Patients Following Surgical Resection and Adjuvant Chemotherapy (PHASE1)
- Clinical Study of a Personalized Neoantigen Cancer Vaccine Combined With Anti-PD-1 and RFA in Patients With Solid Tumors (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |